🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

‼️Gracias Telediarios de TVE por ayudarnos en la concienciación frente al #tabaco con nuestro concurso de Tik Toks ⚡Nuevas formas, mismos riesgos rtve.es/play/videos/te… 🩺Bartomeu Massuti Virginia Calvo Bristol Myers Squibb España & Portugal

Night and day at Portocolom

This really shouldn’t surprise anyone. If you take a disease where 80+% have micromet disease and expose them to SoC first line systemic therapy before local consolidation you will have better outcomes than if you perform local consolidation first. #radonc community cannot

Am I the only one questioning the “unbridled enthusiasm” for cCRT that is based the phase III RTOG 9410 study conducted 30y ago? Can we please revisit sCRT with the vigor it deserves to optimize RT safety and efficacy? Does anyone even use bolus vinblastine q5w anymore? #ASCO25

Drew Moghanaki Wally Curran Jonathan Spicer MD PhD M.Provencio Dr. Julie Brahmer Suresh S. Ramalingam, MD, FASCO Nitin Ohri Salma Jabbour Puneeth Iyengar Amy L. Cummings, MD PhD Interesting point Drew Moghanaki my sense is sequential is used a lot more frequently outside the US, been at this now for 18 years and I don’t think I have ever prescribed vinblastine 🤔 I agree a lot of preconceptions need to be challenged

Bob Dylan - The Times They Are a-Changin' [LIVE IN ENGLAND - 1965] youtu.be/Q9_nWlSX6Us?si… vía YouTube

✅ ‼️ Now online ASCO EduBook article led by Jennifer Carlisle and others from our upcoming Education session June 2. We discuss novel Bispecifics Abs in #NSCLC and Tox management approaches. Sagal Pannu Ayesha Aijaz. Have a read !

⭕ El estudio ATHENEA del Grupo Español de Cáncer de Pulmón inicia apertura de centros. 👉 Ensayo fase II con quimio + atezolizumab en CPNM estadio IIIA/IIIB 🏥ICO Girona, primer centro activo ➡️97 pacientes, 21 centros ¡Gracias a todos los investigadores! #CancerDePulmon #EnsayoClinico #GECP #ATHENEA

Out now & open access in Nature Medicine concurrent with presentation at #ASCO2025 is NeoCOAST-2! I have been delighted to collaborate on the first platform neoadjuvant trial in lung cancer led by Dr. Tina Cascone nature.com/articles/s4159… ! #LCSM 1/6

🙌🏻Today is #NationalCancerSurvivorsDay In 2020, only 30% of patients with early-stage #lungcancer survived 5 years. With #NADIM, a study by Grupo Español de Cáncer de Pulmón, that figure exceeds 65%. 🔬 Chemo + immunotherapy (nivolumab) before surgery. Spanish science that’s changing reality. 👇 Watch

CM77T update; OS still not positive; nice ctDNA clearance data #ASCO25

#ASCO25 M.Provencio shows biomarkers in CM 77T Perioperative ⬆️EFS (HR 0,61) ctDNA clearance 🧬🩸and pCR was associated with EFS in NIVO and placebo arm More clearance and pCR in NIVO arm OS immature Lung 🫁 cancer survival ⬆️ OncoAlert Stephen V Liu, MD Jarushka Naidoo gilberto lopes

#ASCO25 update on CheckMate 77T: Periop nivo vs plb in resectable NSCLC (mFUP 41 mo) M.Provencio 🔹 EFS: 46.6 vs 16.9 mo (HR 0.61), 30-mo 61% vs 43% 🔹 Benefit regardless of KRAS, STK11, KEAP1, PD-L1 status 🔹 ctDNA/pCR linked to EFS 🔹 OS NR trend HR 0.85 (30mo 78% vs 72%)

Congratulations to Charlie Rudin & DeLLphi-304 investigators on this practice-changing trial for our patients with small cell lung cancer Memorial Sloan Kettering Cancer Center Tarlatamab in SCLC after Platinum-Based Chemotherapy | New England Journal of Medicine nejm.org/doi/full/10.10…

Perioperative Nivolumab Sustains EFS Advantage in Resectable NSCLC, With Enriched Benefit in ctDNA–, pCR Responders #NSCLC #LCSM #ASCO25 ASCO M.Provencio onclive.com/view/periopera…

🔬Complete pathological response is the strongest predictor of survival in neoadjuvant chemo-IO in NSCLC. 📈5 years OS = 95% (3 non cancer related deaths) 📈5 years DFS = 88% Kudos for the CM-816 investigators. #ASCO25 #LCSM

Was an honor chairing 🫁 orals with Pramesh CS #ASCO25 were in 30 min we saw more progress than we have seen in over 30 years for #SCLC #IMforte #DeLLphi-304 and #ZG006 TriTE!! Congratulations to all the presenters. This session had two NEJM one The Lancet and one Journal of Clinical Oncology !

Congrats Rafeh!!

🗣️En los primeros análisis del estudio #NADIM, el equipo investigador confirmó algo crucial: el tumor desaparecía por completo tras el tratamiento previo a la cirugía. ➡️Una estrategia innovadora que hoy ya es una realidad clínica. ‼️Conoce cómo se investigó en el laboratorio: